Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of June 2023. The report, dated June 16, 2023, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The document serves as a cover for a press release but does not include the text of that release. Consequently, no guidance, management commentary, risks, contingencies, or unusual items are detailed in the provided content.
Investor Verification Checklist
- Review the full text of the press release dated June 16, 2023 (Exhibit 99.1), which is referenced but not included in this summary.
- Verify the specific operational or clinical updates announced in the press release.
- Check subsequent filings for detailed financial impacts related to the June 2023 announcement.